Colorectal cancer (CRC) is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed in 2012, and South Korea is one of the countries with the highest incidence of CRC \[[@b1-jptm-2017-01-19]\]. Although TNM staging of American Joint Committee on Cancer (AJCC) is the most powerful and reliable tool for prediction of prognosis and therapeutic decision making in CRC patients, the clinical outcome of CRC patients may vary even within the same cancer stage. Despite curative surgery and adjuvant chemotherapy and/or radiation therapy, approximately 17% of stage II CRCs and 33% of stage III CRCs will have a disease recurrence following primary therapy \[[@b2-jptm-2017-01-19]\]. Identification of CRCs with a high risk of recurrence might give a chance of benefit from additional therapy. Many studies are trying to find factors that could more precisely stratify patients into different risk categories.

Recent studies find that tumor microenvironment and tumorstroma interaction are critical in tumor behavior. In tumor microenvironment, cancer-associated fibroblasts have an important role in tumor-stroma interaction and could affect prognosis \[[@b3-jptm-2017-01-19]-[@b7-jptm-2017-01-19]\]. However, there are no specific markers of cancer-associated fibroblasts that have been proven to be related with tumor prognosis. Periostin (POSTN) is a secreted extracellular matrix protein which is originally identified to be expressed in osteoblasts and osteoblast-derived cells. POSTN is normally expressed in not only collagen-rich fibrous connective tissues, including periosteum and periodontal ligament, but also fibroblasts of normal tissue, including stomach and colon \[[@b8-jptm-2017-01-19]\]. POSTN is also expressed in cancer-associated fibroblasts of breast, colon, lung, pancreas, and stomach cancer \[[@b9-jptm-2017-01-19],[@b10-jptm-2017-01-19]\]. POSTN binds integrins, including αvβ3, αvβ5, and α6β4, which leads to the activation of the Akt/protein kinase B and focal adhesion kinase signalling pathways \[[@b11-jptm-2017-01-19]-[@b13-jptm-2017-01-19]\]. POSTN-activated signalling pathways promote angiogenesis, cellular survival, and resistance to hypoxia-induced cell death \[[@b8-jptm-2017-01-19],[@b14-jptm-2017-01-19]\]. POSTN is also involved in epithelial-mesenchymal transition of tumor \[[@b8-jptm-2017-01-19]\]. Recent studies show that POSTN is associated with tumor invasiveness and poor prognosis in several malignancies \[[@b15-jptm-2017-01-19]-[@b17-jptm-2017-01-19]\].

In the present study, we analyzed 1,125 CRC cases for their expression status of POSTN using immunohistochemistry and correlated POSTN expression with molecular features of CRCs, including CpG island methylator phenotype (CIMP), microsatellite instability (MSI), and clinicopathological features of CRC, including survival of patients. We tried to identify whether POSTN expression in cancer-associated fibroblast can be a prognostic marker in CRC.

MATERIALS AND METHODS
=====================

Tissue samples
--------------

A consecutive series of CRC cases were retrieved from the surgical files of the Department of Pathology, Seoul National University Hospital, Seoul, Korea. Among the patients who underwent surgical resection for primary CRC from 2004 to 2007, we excluded those with neo-adjuvant treatment, non-invasive cancers, familial adenomatous polyposis, multiple or recurrent tumors, and a history of other malignancy within 5 years. Demographic data and clinicopathological information were retrieved from electronic medical records. Two pathologists (J.M.B. and G.H.K.) reviewed hematoxylin and eosin--stained tissue slides for the degree of histologic differentiation which was categorized as well-moderate versus poor (\> 50% vs ≤ 50%, respectively). Staging was classified according to the sixth edition guidelines of the AJCC. Hematoxylin and eosin--stained slides were also reviewed for evaluation of tumor budding, which is defined to be present when five or more buddings are present at × 200 magnification. Status of tumor infiltrating lymphocytes was divided into high and low (≥ 8 at × 400 magnification and \< 8 at × 400 magnification, respectively). The study was approved by Institutional Ethics Committee of Seoul National University Hospital which waived the requirement to obtain informed consent (approval No. 1502-029-647).

Evaluation of POSTN expression
------------------------------

After reviewing the hematoxylin and eosin tissue slides, representative areas of the tumor invasive front were selected and marked. Two-millimeter-core tissues were harvested from individual paraffin-embedded colon cancer tissues and were arranged in a new recipient paraffin block using a trephine apparatus (Superbiochip Laboratories, Seoul, Korea). Immunohistochemical analysis was performed with commercially available antibody against POSTN (1:200, HPA012306, Sigma, St. Louis, MO, USA). Two pathologists (H.J.O. and J.M.B.) independently evaluated POSTN immunohistochemistry. POSTN expression in tumor stroma showed homogeneous staining intensity and the level of POSTN expression was graded as 0 (negative), 1 (weak), 2 (moderate), and 3 (strong) ([Fig. 1](#f1-jptm-2017-01-19){ref-type="fig"}). Then, grades 0--2 and 3 were categorized as POSTN-low and POSTN-high, respectively.

*BRAF* and *KRAS* mutation and microsatellite instability analysis
------------------------------------------------------------------

Through microscopic examination, representative tumor areas in each case were marked and microdissected. The dissected tissues were subject to incubation at 55°C with lysis buffer and proteinase K for 2 days. Allele specific polymerase chain reaction for *BRAF* codon 600 and direct sequencing of *KRAS* codons 12 and 13 were performed. The MSI status of each tumor tissue versus normal tissue was determined by five National Cancer Institute markers including BAT25, BAT26, D2S123, D5S346, and D17S250. High MSI status was defined as when tumor DNA had altered alleles compared to normal DNA in two or more markers. Low MSI status was defined as when tumor DNA had altered allele compared to normal DNA in one marker. Microsatellite stable was defined as when no altered allele was present in tumor DNA.

CIMP analysis
-------------

CIMP status was examined by MethyLight assay. Bisulfite modified DNA was subject to MethyLight assay which was performed as previously described \[[@b18-jptm-2017-01-19]\]. Methylation statuses of eight CIMP-specific CpG islands (*CACNA1G*, *CDKN2A*, *CRABP1*, *IGF2*, *MLH1*, *NEUROG1*, *RUNX3*, and *SOCS1*) were quantified. CIMP-high was defined as five or more markers methylated, and CIMP-low was defined as four or less markers methylated out of eight. CIMP-0 was defined as no methylated marker.

Statistical analysis
--------------------

SAS software (ver. 9.4 for Microsoft Windows, SAS Institute Inc., Cary, NC, USA) was used for the statistical analysis in our cohort. To compare clinicopathologic characteristics to stromal POSTN expression, we performed Pearson's chi-square test. The age of CRC group according to stromal POSTN expression was compared using Wilcoxon's rank-sum test. For the survival analysis, 5-year cancer-specific survival (CSS) and 5-year progression-free survival (PFS) were calculated using the log-rank test with a Kaplan-Meier curve. Hazard ratios (HRs) were calculated using the Cox proportional hazard model. The assumption of the proportional hazards was verified by plotting the log{--log\[S(t)\]} against the time of the study. In the modeling process, all variables that were associated with PFS with a p \< .10 were entered into an initial model; these variables were subsequently reduced by backward elimination. All statistical tests were two-sided, and statistical significance was defined as p \< .05.

RESULTS
=======

Patient characteristics
-----------------------

In a total of 1,135 CRC patients, the median age at diagnosis was 62 years (range, 20 to 90 years). The male to female ratio was 1.49:1 (673 males and 452 females). Tumor location was proximal colon (proximal to splenic flexure) in 277 patients (24.6%), distal colon in 438 patients (38.9%), and rectum in 410 patients (36.4%). *KRAS* mutation and *BRAF* mutation were observed in 313 (27.8%) and 48 patients (4.3%), respectively. In microsatellite analysis, microsatellite stable, MSI-low, and MSI-high were observed in 964 (85.7%), 73 (6.5%), and 88 (7.8%) patients, respectively. In CIMP analysis, CIMP-0, CIMP-low, and CIMP-high were observed in 510 (45.3%), 553 (49.2%), and 62 (5.5%) patients, respectively. Median follow-up duration was 69.8 months (range, 0.3 to 150.2 months). Seven hundred seventy-nine patients received 5-fluorouracil (5-FU)-based adjuvant chemotherapy.

Clinicopathological features of CRCs according to stromal POSTN expression
--------------------------------------------------------------------------

Of 1,125 CRC cases, 33 (2.9%), 296 (26.3%), 492 (43.7%), and 304 (27.0%) patients showed stromal POSTN expression from grade 0 to 3, respectively. POSTN-low CRCs were 821 (73.0%) and POSTN-high CRCs were 304 (27.0%) ([Table 1](#t1-jptm-2017-01-19){ref-type="table"}). CRCs with stromal POSTN-high expression were associated with proximal location (35.2% in POSTN-high group vs 20.7% in POSTN-low group, p \< .001), infiltrative growth pattern (44.7% vs 30.7%, p \< .001), advanced T, N, M category (p \< .001), frequent tumor budding (80.9% vs 68.2%, p \< .001) and luminal necrosis (94.4% vs 89.6%, p = .014) compared with CRCs with stromal POSTN-low expression. In molecular aspect, CRCs with stromal POSTN-high expression showed higher frequency of CIMP-high (7.9% vs 4.6%, p = .030) and *BRAF* mutation (6.3% vs 3.5%, p = .046) compared with CRCs with stromal POSTN-low expression. However, the frequency of MSI-high and *KRAS* mutation were not statistically associated with stromal POSTN expression.

Prognostic implication of stromal POSTN expression in CRCs
----------------------------------------------------------

When we performed univariate survival analysis, CRCs with stromal POSTN-high expression showed worse 5-year PFS (HR, 1.80; 95% CI, 1.47 to 2.20; p \< .001) ([Fig. 2A](#f2-jptm-2017-01-19){ref-type="fig"}) and worse 5-year CSS (HR, 2.00; 95% CI, 1.52 to 2.63; p \< .001) ([Fig. 2B](#f2-jptm-2017-01-19){ref-type="fig"}) compared with CRCs with stromal POSTN-low expression. In multivariate survival analysis, stromal POSTN-high expression was an independent prognostic indicator of poor 5-year CSS (HR, 1.50; 95% CI, 1.13 to 2.00; p = .006) ([Table 2](#t2-jptm-2017-01-19){ref-type="table"}) and poor 5-year PFS (HR, 1.38; 95% CI, 1.12 to 1.70; p = .003) ([Table 3](#t3-jptm-2017-01-19){ref-type="table"}).

DISCUSSION
==========

Recent studies show POSTN is overexpressed in cancer stroma of various malignancies, including colorectal, breast, lung, pancreatic, ovarian, gastric, head and neck, thyroid and prostate cancer as well as in glioblastoma \[[@b19-jptm-2017-01-19]\]. POSTN is thought to play important roles in tumorigenesis, such as invasiveness, metastasis, angiogenesis, lymphangiogenesis, and chemoresistance \[[@b8-jptm-2017-01-19],[@b15-jptm-2017-01-19],[@b20-jptm-2017-01-19]-[@b24-jptm-2017-01-19]\]. In this study, we found that POSTN is overexpressed in 304 (27.0%) out of 1,125 cases, which is consistent with the results of other studies in several malignancies \[[@b19-jptm-2017-01-19]\]. Our study demonstrated that high POSTN expression is correlated with several aggressive clinicopathological features of CRCs. First, stromal POSTN expression was higher in CRCs of infiltrative growth pattern than CRCs of fungating growth pattern, which implies that POSTN is involved in infiltrative growth of tumor. Second, POSTN expression was correlated with T, N, or M category. These results suggest that POSTN might participate in tumor progression and nodal or distant metastasis, which is consistent with the results of a recent study that POSTN expression is higher in distant metastatic lesion than in matched primary colorectal lesion \[[@b17-jptm-2017-01-19]\]. Cell line studies demonstrated that POSTN induces invasive activity and bestows a metastatic potential to HEK 293T cells which are tumorigenic but nonmetastatic \[[@b11-jptm-2017-01-19],[@b17-jptm-2017-01-19]\]. These results support the idea that POSTN might contribute to metastasis of tumor cells. Third, high tumor budding status was correlated with high POSTN expression. Several studies addressed that tumor budding should be regarded as a biomarker of poor prognosis, correlated with epithelial mesenchymal transition \[[@b25-jptm-2017-01-19]-[@b28-jptm-2017-01-19]\]. A cell line study has demonstrated that stable transfection of POSTN induced epithelial-mesenchymal transition and increased invasive activity in HEK 293T cells \[[@b11-jptm-2017-01-19]\]. However, our present study has several limitations. First, this study is a retrospective study in a single institution. Second, stromal POSTN expression was evaluated in tissue microarray.

In our study, stromal POSTN expression was associated with CIMP-high and *BRAF* mutation. Because CIMP-high and *BRAF* mutation are hallmarks of molecular alterations in serrated neoplasia pathway, we can presume that stromal POSTN overexpression is associated with serrated neoplasia pathway. In a study by De Sousa *et al* \[[@b29-jptm-2017-01-19]\]., CCS3 subtype, which is related with serrated neoplasia pathway, showed overexpression of genes associated with epithelial mesenchymal transition and matrix remodeling. Recently, Fessler *et al* \[[@b30-jptm-2017-01-19]\]. demonstrated the induction of a mesenchymal phenotype upon transforming growth factor β treatment in a genetically engineered organoid culture carrying *BRAF* V600E mutation. In serrated neoplasia pathway, three molecular groups are known to be involved. One is *BRAF*-mutant/CIMP-high/ MSI-high subgroup, another is *BRAF*-mutant/CIMP-high/microsatellite stable (MSS) subgroup, and the other is *KRAS*-mutant/CIMP-low/MSS subgroup \[[@b31-jptm-2017-01-19],[@b32-jptm-2017-01-19]\]. In this study, stromal POSTN overexpression was related with *BRAF*-mutant/CIMP-high/MSS subgroup (data not shown). Moreover, some clinicopathological features associated with CIMP, such as right colon preponderance, poor differentiation, high rates of tumor budding, frequent lymphatic, vascular, or perineural invasion and nodal metastasis, were more frequently observed in POSTN-high colon cancer compared with POSTN-low colon cancer. Further molecular test is needed to elucidate the relation between high POSTN stromal expression and serrated neoplasia pathway.

An accumulating series of study results indicate that cancer+associated fibroblasts contribute to chemo-resistance and poor patient survival \[[@b15-jptm-2017-01-19],[@b17-jptm-2017-01-19],[@b28-jptm-2017-01-19]\]. According to Xu *et al*., medium to high stromal POSTN expression was an independent predictor of poor disease-free survival and disease-specific survival. They also presented the association of chemo-resistance and stromal POSTN expression in stage II CRCs and stage III CRCs with chemotherapy history. In *in vitro* study, SW480 and HT29 cells cultured in stromal POSTN-enriched media showed chemoresistance to 5-FU. Recombinant POSTN increased proliferation and phosphorylation of Akt in SW480 and HT29 cells. Furthermore, the proliferation and phosphorylation of Akt were inhibited by phosphoinositide 3-kinase inhibitor LY294002 \[[@b17-jptm-2017-01-19],[@b24-jptm-2017-01-19]\]. In our present study, stromal POSTN-high expression was an independent prognostic indicator of poor 5-year CSS and 5-year PFS. However, we could not confirm the chemo-resistance effect of stromal POSTN expression in our cohort (data not shown).

In conclusion, our findings suggest that immunohistochemical evaluation of stromal POSTN expression could be utilized for the identification of a subset of CRCs with poor prognosis. To determine whether stromal POSTN expression status is a prognostic marker of CRC, further studies are needed to validate this finding with an independent series of large-scaled CRC cases.
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###### 

Clinicopathologic characteristics of colorectal cancers according to the stromal POSTN expression

  Variable                                          POSTN-low (n = 821, 73.0%)   POSTN-high (n = 304, 27.0%)   p-value
  -------------------------------- ---------------- ---------------------------- ----------------------------- ---------
  Age (yr)                                          62 (20--87)                  62 (29--90)                   .932
  Sex                              Male             500 (60.9)                   173 (56.9)                    .225
  Female                           321 (39.1)       131 (43.1)                                                 
  Location                         Proximal         170 (20.7)                   107 (35.2)                    \< .001
  Distal                           336 (40.9)       102 (33.5)                                                 
  Rectum                           315 (38.4)       95 (31.3)                                                  
  Growth pattern                   Fungating        569 (69.3)                   168 (55.3)                    \< .001
  Fungating                        252 (30.7)       136 (44.7)                                                 
  T category                       T1,2             192 (23.4)                   18 (5.9)                      \< .001
  T3,4                             629 (76.6)       286 (94.1)                                                 
  N category                       N0               454 (55.3)                   117 (38.5)                    \< .001
  N1,2                             367 (44.7)       187 (61.5)                                                 
  M category                       0                712 (86.7)                   222 (73.0)                    \< .001
  1                                109 (13.3)       82 (27.0)                                                  
  Stage                            I, II            432 (52.6)                   104 (34.2)                    \< .001
  III, IV                          109 (13.3)       200 (65.8)                                                 
  Differentiation                  Differentiated   802 (97.7)                   284 (93.4)                    .001
  Undifferentiated                 19 (2.3)         20 (6.6)                                                   
  Tumor budding                    Absent           261 (31.8)                   58 (19.1)                     \< .001
  Present                          560 (68.2)       246 (80.9)                                                 
  Dirty necrosis                   Absent           85 (10.4)                    17 (5.6)                      .014
  Present                          736 (89.6)       287 (94.4)                                                 
  Crohn-like reaction              Absent           703 (85.6)                   251 (82.6)                    .204
  Present                          118 (14.4)       53 (17.4)                                                  
  Tumor-infiltrating lymphocytes   High (≥ 8/HPF)   599 (73.0)                   233 (76.6)                    .211
  Low (\< 8/HPF)                   222 (27.0)       71 (23.4)                                                  
  Serration                        Absent           793 (96.6)                   288 (94.7)                    .155
  Present                          28 (3.4)         16 (5.3)                                                   
  Mucin production                 Absent           727 (88.5)                   265 (87.2)                    .525
  Present                          94 (11.5)        39 (12.8)                                                  
  CIMP                             CIMP-0           387 (47.1)                   123 (40.5)                    .030
  CIMP-low                         396 (48.2)       157 (51.6)                                                 
  CIMP-high                        38 (4.6)         24 (7.9)                                                   
  MSI                              MSS              702 (85.5)                   262 (86.2)                    .959
  MSI-low                          54 (6.6)         19 (6.2)                                                   
  MSI-high                         65 (7.9)         23 (7.6)                                                   
  *KRAS* mutation                  Wild type        602 (73.3)                   210 (69.1)                    .158
  Mutant                           219 (26.7)       94 (30.9)                                                  
  *BRAF* mutation (n = 1,124)      Wild type        791 (96.5)                   285 (93.7)                    .046
  Mutant                           29 (3.5)         19 (6.3)                                                   

Values are presented as median (range) or number (%).

POSTN, periostin; HPF, high-power field; CIMP, CpG island methylator phenotype; MSI, microsatellite instability.

###### 

Univariate and multivariate analysis with respect to 5-year cancer-specific survival

  Variable                                    Univariate          Multivariate                       
  ------------------------------------------- ------------------- -------------- ------------------- ---------
  Gross (infiltrative/fungating)              1.87 (1.32--2.66)   \< .001        1.64 (1.24--2.18)   .001
  Stage (III, IV/I, II)                       4.52 (3.26--6.26)   \< .001        6.30 (4.27--9.29)   \< .001
  Differentiation (PD/WD, MD)                 3.41 (2.05--5.67)   \< .001        2.15 (1.27--3.62)   .013
  *BRAF* (mutant/wild type)                   1.92 (1.15--3.19)   .012           1.92 (1.11--3.34)   .041
  Chemotherapy (treated/not-treated)          0.94 (0.71--1.25)   .655           0.38 (0.28--0.52)   \< .001
  POSTN (high/low)                            2.00 (1.52--2.64)   \< .001        1.50 (1.13--2.00)   .006
  Tumor location (right/left)                 1.56 (1.19--2.06)   .002           1.46 (1.09--1.96)   .011
  Tumor-infiltrating lymphocytes (high/low)   0.69 (0.49--0.97)   .032           \-                  .051
  Budding (present/absent)                    1.90 (1.36--2.66)   \< .001        \-                  .129
  Crohn-like reaction (present/absent)        0.71 (0.48--1.06)   .095           \-                  .305
  Age (≥ 65 yr/\< 65 yr)                      1.49 (1.15--1.93)   .003           \-                  .053
  CIMP (CIMP-H/CIMP-0, L)                     1.91 (1.21--3.02)   .006           \-                  .632
  Sex (male/female)                           1.04 (0.80--1.36)   .762           \-                  \-
  Necrosis (present/absent)                   1.11 (0.70--1.78)   .652           \-                  \-
  Serration (present/absent)                  1.42 (0.80--2.54)   .235           \-                  \-
  Mucin (present/absent)                      1.32 (0.92--1.90)   .136           \-                  \-
  MSI (MSI-H/MSS, MSI-L)                      0.82 (0.48--1.41)   .476           \-                  \-
  *KRAS* (mutant/wild type)                   1.12 (0.84--1.49)   .440           \-                  \-

HR, hazard ratio; PD, poorly differentiated; WD, well differentiated; MD, moderately differentiated; POSTN, periostin; CIMP, CpG island methylator phenotype; CIMP-H, CIMP-high; CIMP-L, CIMP-low; MSI, microsatellite instability; MSI-H, MSI-high; MSS, microsatellite stable; MSI-L, MSI-low.

###### 

Univariate and multivariate analysis with respect to 5-year progression-free survival

  Variable                                    Univariate          Multivariate                       
  ------------------------------------------- ------------------- -------------- ------------------- ---------
  Gross (infiltrative/fungating)              1.96 (1.61--2.39)   \< .001        1.43 (1.17--1.76)   .001
  Stage (III, IV/I, II)                       4.72 (3.71--6.02)   \< .001        4.75 (3.63--6.23)   \< .001
  Differentiation (PD/WD, MD)                 3.32 (2.28--4.85)   \< .001        1.85 (1.26--2.71)   .002
  *BRAF* (mutant/wild type)                   1.61 (1.06--2.45)   .027           1.72 (1.12--2.63)   .013
  Chemotherapy (treated/not-treated)          1.40 (1.11--1.76)   .004           0.59 (0.46--0.76)   \< .001
  POSTN (high/low)                            1.80 (1.47--2.20)   \< .001        1.40 (1.08--1.83)   .012
  Budding (present/absent)                    2.15 (1.66--2.79)   \< .001        1.51 (1.15--1.97)   .003
  Crohn-like reaction (present/absent)        0.72 (0.53--0.98)   .034           \-                  .302
  Tumor-infiltrating lymphocytes (high/low)   0.70 (0.55--0.89)   .004           \-                  .089
  Tumor location (right/left)                 1.22 (0.98--1.51)   .080           \-                  .773
  Age (≥ 6 yr/\< 65 yr)                       1.22 (1.00--1.49)   .046           \-                  .098
  CIMP (CIMP-H/CIMP-0, L)                     1.44 (0.98--2.12)   .061           \-                  .277
  Sex (male/female)                           0.94 (0.77--1.14)   .514           \-                  \-
  Necrosis (present/absent)                   1.14 (0.80--1.62)   .463           \-                  \-
  Serration (present/absent)                  1.32 (0.83--2.08)   .244           \-                  \-
  Mucin (present/absent)                      1.12 (0.84--1.50)   .448           \-                  \-
  MSI (MSI-H/MSS, MSI-L)                      0.80 (0.54--1.20)   .285           \-                  \-
  *KRAS* (mutant/wild type)                   1.05 (0.85--1.31)   .633           \-                  \-

HR, hazard ratio; CI, confidence interval; PD, poorly differentiated; WD, well differentiated; MD, moderately differentiated; POSTN, periostin; CIMP, CpG island methylator phenotype; CIMP-H, CIMP-high; MSI, microsatellite instability; MSI-H, MSI-high; MSS, microsatellite stable; MSI-L, MSI-low.
